vs
CytomX Therapeutics, Inc.（CTMX）与Laird Superfood, Inc.（LSF）财务数据对比。点击上方公司名可切换其他公司
CytomX Therapeutics, Inc.的季度营收约是Laird Superfood, Inc.的1.4倍（$18.7M vs $13.3M），CytomX Therapeutics, Inc.净利率更高（-0.8% vs -13.2%，领先12.4%），Laird Superfood, Inc.同比增速更快（15.0% vs -25.7%），过去两年Laird Superfood, Inc.的营收复合增速更高（16.1% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
Laird Superfood是一家主营植物基功能性超级食品的企业，产品涵盖精品咖啡奶精、补水混合饮品、营养补充剂、植物能量零食等，面向健康意识较强的消费群体，主要在北美市场通过电商及线下零售渠道销售，主打可持续采购的清洁配方。
CTMX vs LSF — 直观对比
营收规模更大
CTMX
是对方的1.4倍
$13.3M
营收增速更快
LSF
高出40.7%
-25.7%
净利率更高
CTMX
高出12.4%
-13.2%
两年增速更快
LSF
近两年复合增速
-15.9%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $13.3M |
| 净利润 | $-154.0K | $-1.8M |
| 毛利率 | — | 34.1% |
| 营业利润率 | -6.9% | -13.5% |
| 净利率 | -0.8% | -13.2% |
| 营收同比 | -25.7% | 15.0% |
| 净利润同比 | 97.6% | -341.4% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXLSF
| Q4 25 | — | $13.3M | ||
| Q3 25 | — | $12.9M | ||
| Q2 25 | $18.7M | $12.0M | ||
| Q1 25 | $50.9M | $11.7M | ||
| Q4 24 | $38.1M | $11.6M | ||
| Q3 24 | $33.4M | $11.8M | ||
| Q2 24 | $25.1M | $10.0M | ||
| Q1 24 | $41.5M | $9.9M |
净利润CTMXLSF
| Q4 25 | — | $-1.8M | ||
| Q3 25 | — | $-975.1K | ||
| Q2 25 | $-154.0K | $-362.2K | ||
| Q1 25 | $23.5M | $-156.2K | ||
| Q4 24 | $18.9M | $-398.4K | ||
| Q3 24 | $5.7M | $-166.1K | ||
| Q2 24 | $-6.5M | $-239.1K | ||
| Q1 24 | $13.8M | $-1.0M |
毛利率CTMXLSF
| Q4 25 | — | 34.1% | ||
| Q3 25 | — | 36.5% | ||
| Q2 25 | — | 39.9% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | — | 38.6% | ||
| Q3 24 | — | 43.0% | ||
| Q2 24 | — | 41.8% | ||
| Q1 24 | — | 40.0% |
营业利润率CTMXLSF
| Q4 25 | — | -13.5% | ||
| Q3 25 | — | -7.7% | ||
| Q2 25 | -6.9% | -3.3% | ||
| Q1 25 | 44.4% | -1.9% | ||
| Q4 24 | 46.4% | -4.1% | ||
| Q3 24 | 12.3% | -2.3% | ||
| Q2 24 | -33.7% | -3.4% | ||
| Q1 24 | 28.1% | -11.0% |
净利率CTMXLSF
| Q4 25 | — | -13.2% | ||
| Q3 25 | — | -7.6% | ||
| Q2 25 | -0.8% | -3.0% | ||
| Q1 25 | 46.2% | -1.3% | ||
| Q4 24 | 49.6% | -3.4% | ||
| Q3 24 | 17.2% | -1.4% | ||
| Q2 24 | -26.0% | -2.4% | ||
| Q1 24 | 33.3% | -10.3% |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $5.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $11.5M |
| 总资产 | $175.1M | $19.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMXLSF
| Q4 25 | — | $5.1M | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | $49.0M | $3.9M | ||
| Q1 25 | $47.6M | $7.0M | ||
| Q4 24 | $38.1M | $8.3M | ||
| Q3 24 | $40.6M | $7.9M | ||
| Q2 24 | $43.2M | $7.6M | ||
| Q1 24 | $36.2M | $7.1M |
股东权益CTMXLSF
| Q4 25 | — | $11.5M | ||
| Q3 25 | — | $12.8M | ||
| Q2 25 | $119.9M | $13.4M | ||
| Q1 25 | $25.0M | $13.3M | ||
| Q4 24 | $-456.0K | $13.2M | ||
| Q3 24 | $-23.5M | $13.1M | ||
| Q2 24 | $-31.2M | $12.6M | ||
| Q1 24 | $-31.7M | $12.7M |
总资产CTMXLSF
| Q4 25 | — | $19.2M | ||
| Q3 25 | — | $18.9M | ||
| Q2 25 | $175.1M | $20.4M | ||
| Q1 25 | $98.5M | $21.5M | ||
| Q4 24 | $120.5M | $19.3M | ||
| Q3 24 | $139.0M | $18.8M | ||
| Q2 24 | $159.2M | $18.0M | ||
| Q1 24 | $184.7M | $17.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $68.4K |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | — |
| 自由现金流率自由现金流/营收 | -84.6% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-77.7M | — |
8季度趋势，按日历期对齐
经营现金流CTMXLSF
| Q4 25 | — | $68.4K | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | $-15.8M | $-2.8M | ||
| Q1 25 | $-21.0M | $-1.3M | ||
| Q4 24 | $-19.9M | $339.2K | ||
| Q3 24 | $-20.7M | $305.8K | ||
| Q2 24 | $-19.5M | $642.7K | ||
| Q1 24 | $-26.0M | $-422.3K |
自由现金流CTMXLSF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
自由现金流率CTMXLSF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
资本支出强度CTMXLSF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
现金转化率CTMXLSF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
